Intermediate filament transcription in astrocytes is repressed by proteasome inhibition
Open Access
- 30 March 2009
- journal article
- research article
- Published by Wiley in The FASEB Journal
- Vol. 23 (8) , 2710-2726
Abstract
Increased expression of the astrocytic intermediate filament protein glial fibrillary acidic protein (GFAP) is a characteristic of astrogliosis. This process occurs in the brain during aging and neurodegeneration and coincides with impairment of the ubiquitin proteasome system. Inhibition of the proteasome impairs protein degradation;therefore, we hypothesized that the increase in GFAP may be the result of impaired proteasomal activity in astrocytes. We investigated the effect of proteasome inhibitors on GFAP expression and other intermediate filament proteins in human astrocytoma cells and in a rat brain model for astrogliosis. Extensive quantitative RT‐PCR, immunocyto‐ chemistry, and Western blot analysis resulted unexpectedly in a strong decrease of GFAP mRNA to in vitro . We show that the proteasome alters GFAP promoter activity, possibly mediated by transcription factors as demonstrated by a GFAP promoter‐luciferase assay and RT 2 Profiler PCR array for human transcription factors. Most important, we demonstrate that proteasome inhibitors also reduce GFAP and vimentin expression in a rat model for induced astrogliosis in vivo . Therefore, proteasome inhibitors could serve as a potential therapy to modulate astrogliosis associated with CNS injuries and disease.— Middeldorp, J.,Kamphuis, W., Sluijs, J. A., Achoui, D., Leenaars, C. H. C., Feenstra, M. G. P., Van Tijn, P., Fischer, D. F., Berkers, C., Ovaa, H., Quinlan, R. A., Hol, E. M. Intermediate filament transcription in astrocytes is repressed by proteasome inhibition. FASEBJ. 23, 2710–2726 (2009)Keywords
Funding Information
- Hersenstichting
- Internationale Stichting Alzheimer Onderzoek
This publication has 103 references indexed in Scilit:
- Phase I Trial Using Proteasome Inhibitor Bortezomib and Concurrent Temozolomide and Radiotherapy for Central Nervous System MalignanciesInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2009
- Regulation of Acetylation at the Major Histocompatibility Complex Class II Proximal Promoter by the 19S Proteasomal ATPase Sug1Molecular and Cellular Biology, 2008
- Glial Fibrillary Acidic Protein Filaments Can Tolerate the Incorporation of Assembly-compromised GFAP-δ, but with Consequences for Filament Organization and αB-Crystallin AssociationMolecular Biology of the Cell, 2008
- Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple MyelomaNew England Journal of Medicine, 2008
- STAT3 is a Critical Regulator of Astrogliosis and Scar Formation after Spinal Cord InjuryThe Journal of Neuroscience, 2008
- Egr-1 Regulates Expression of the Glial Scar Component Phosphacan in Astrocytes after Experimental StrokeThe American Journal of Pathology, 2008
- Endothelin-1 Regulates Astrocyte Proliferation and Reactive Gliosis via a JNK/c-Jun Signaling PathwayJournal of Neuroscience, 2008
- GFAP and its role in Alexander diseaseExperimental Cell Research, 2007
- Astrocyte activation and reactive gliosisGlia, 2005
- Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's diseaseAnnals of Neurology, 2004